Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole secondary prophylaxis after allogeneic stem cell transplantation
2004-000365-35Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of voriconazole in invasive mycoses, sponsored by Pfizer. Primary endpoint: Rate of occurrence of proven or probable invasive fungal infection through 12 months. Started Sep 2004; status: completed.
02
Drugs
voriconazole
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on 2004-000365-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000365-35.